Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olmutinib in T790M-positive NSCLC using BAL EV DNA
NCT03228277Phase 2Completed
- Sponsor
- Konkuk University Medical Center
- Start
- Jul 2017
- Primary completion
- Jul 2018
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of olmutinib in non-small cell lung cancer (NSCLC), sponsored by Konkuk University Medical Center. Started Jul 2017; status: completed.
02
Drugs
olmutinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03228277.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03228277.